Bayer, Onyx Report Primary Endpoint of Phase 3 Study Results of NEXAVAR as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation was Not Met
March 11, 2014 at 05:33 AM EDT
Bayer HealthCare Pharmaceuticals (OTC: BAYRY) and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a ...
